Salah-Eddin Al-Batran
萨拉赫-埃丁·阿尔-巴特兰
MD
Director, Institute of Clinical Cancer Research (IKF) at UCT Frankfurt; Professor of Medical Oncology法兰克福大学肿瘤中心临床癌症研究所（IKF）主任，医学肿瘤学教授
👥Biography 个人简介
Salah-Eddin Al-Batran, MD is Director of the Institute of Clinical Cancer Research (IKF) at UCT Frankfurt and Professor of Medical Oncology at Krankenhaus Nordwest, Frankfurt. He is internationally recognized as the principal investigator of the FLOT4 trial—the landmark phase III study that established the FLOT (docetaxel, oxaliplatin, leucovorin, fluorouracil) regimen as the perioperative chemotherapy standard for resectable gastric and gastroesophageal junction adenocarcinoma in Europe and globally. Dr. Al-Batran led the design, conduct, and analysis of FLOT4 within the AIO (Arbeitsgemeinschaft Internistische Onkologie) cooperative group framework, demonstrating that FLOT achieved superior overall survival, progression-free survival, and pathologic complete response rates compared to ECF/ECX. He has subsequently led PETRARCA, a phase II trial exploring the addition of trastuzumab and pertuzumab to perioperative FLOT in HER2-positive resectable gastric cancer, yielding high pCR rates and providing proof-of-concept for HER2-directed neoadjuvant intensification. Dr. Al-Batran's research program spans optimization of perioperative regimens, biomarker-stratified perioperative trials, and integration of immunotherapy into the surgical treatment pathway for gastric cancer.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
FLOT4 — Establishing FLOT as Perioperative Standard in Gastric/GEJ Adenocarcinoma
Designed and led FLOT4, the phase III AIO trial demonstrating that perioperative FLOT achieved significantly longer overall survival (median 50 vs 35 months) and higher pCR rates (15% vs 6%) compared to ECF/ECX in resectable gastric and GEJ adenocarcinoma, establishing FLOT as the new European and global perioperative standard.
PETRARCA — HER2-Directed Perioperative Intensification in Resectable Gastric Cancer
Led PETRARCA, a phase II/III trial showing that adding trastuzumab and pertuzumab to perioperative FLOT in HER2-positive resectable gastric/GEJ cancer achieved a pCR rate of 35% (versus 12% with FLOT alone), demonstrating that HER2-directed intensification of the perioperative approach substantially improves pathologic response.
Oxaliplatin-Based Chemotherapy Development in Advanced Gastric Cancer
Conducted AIO phase II and III studies demonstrating the non-inferiority and improved tolerability of oxaliplatin-based regimens (FLO: fluorouracil, leucovorin, oxaliplatin) compared to cisplatin-based counterparts in advanced gastric cancer, facilitating the shift from cisplatin to oxaliplatin in gastric cancer chemotherapy backbones.
Neoadjuvant Immunotherapy Integration in Resectable Gastric Cancer
Designed and led early trials exploring the integration of PD-1 and PD-L1 checkpoint inhibitors into FLOT-based perioperative regimens in resectable gastric cancer, including the DANTE and NEONIPIGA trials, establishing proof-of-concept for immunotherapy-based perioperative intensification particularly in MSI-H disease.
Representative Works 代表性著作
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4)
The Lancet (2019)
Landmark FLOT4 phase III trial establishing FLOT as the perioperative standard, with superior OS, PFS, and pCR versus ECF/ECX in resectable gastric/GEJ adenocarcinoma.
Trastuzumab and pertuzumab in addition to FLOT versus FLOT alone for perioperative treatment of patients with HER2-positive, locally advanced gastric or gastroesophageal junction adenocarcinoma (PETRARCA)
Annals of Oncology (2021)
Phase II PETRARCA trial demonstrating that adding trastuzumab and pertuzumab to FLOT achieved 35% pCR in HER2-positive resectable gastric/GEJ cancer, validating HER2-directed perioperative intensification.
Phase III comparison of FLO versus FLP for first-line treatment of advanced gastric cancer (AIO-Studiengruppe)
Journal of Clinical Oncology (2008)
Randomized AIO trial demonstrating that oxaliplatin-based FLO was at least as active as cisplatin-based FLP and better tolerated in advanced gastric cancer, supporting oxaliplatin adoption in gastric cancer chemotherapy.
Nivolumab plus ipilimumab versus oxaliplatin plus fluorouracil as perioperative treatment of resectable gastric cancer (DANTE)
Nature Medicine (2024)
Phase II/III DANTE trial investigating FLOT plus nivolumab versus FLOT alone in resectable gastric cancer, with early pCR data supporting immune checkpoint integration into the perioperative pathway.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-04-06 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 萨拉赫-埃丁·阿尔-巴特兰 的研究动态
Follow Salah-Eddin Al-Batran's research updates
留下邮箱，当我们发布与 Salah-Eddin Al-Batran（UCT (Universitäres Centrum für Tumorerkrankungen) Frankfurt / Krankenhaus Nordwest, Frankfurt）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment